BIOMAT Database Logo BIOMAT Database Logo

Poliomyelitis prevention: enhanced-potency inactivated poliomyelitis vaccine--supplementary statement. 1987

UI MeSH Term Description Entries
D007115 Immunization Schedule Schedule giving optimum times usually for primary and/or secondary immunization. Immunization Schedules,Schedule, Immunization,Schedules, Immunization
D007223 Infant A child between 1 and 23 months of age. Infants
D011051 Poliomyelitis An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5) Infantile Paralysis,Polio,Poliomyelitis, Nonpoliovirus,Poliomyelitis, Preparalytic,Encephalitis, Polio,Epidemic Acute Poliomyelitis,Polio Encephalitis,Poliomyelitis Infection,Poliomyelitis, Acute,Acute Poliomyelitis,Acute Poliomyelitis, Epidemic,Infection, Poliomyelitis,Infections, Poliomyelitis,Nonpoliovirus Poliomyelitis,Paralysis, Infantile,Poliomyelitides, Preparalytic,Poliomyelitis Infections,Poliomyelitis, Epidemic Acute,Polios,Preparalytic Poliomyelitis
D011054 Poliovirus Vaccine, Inactivated A suspension of formalin-inactivated poliovirus grown in monkey kidney cell tissue culture and used to prevent POLIOMYELITIS. Salk Vaccine,Inactivated Poliovirus Vaccine,Vaccine, Inactivated Poliovirus,Vaccine, Salk
D011055 Poliovirus Vaccine, Oral A live vaccine containing attenuated poliovirus, types I, II, and III, grown in monkey kidney cell tissue culture, used for routine immunization of children against polio. This vaccine induces long-lasting intestinal and humoral immunity. Killed vaccine induces only humoral immunity. Oral poliovirus vaccine should not be administered to immunocompromised individuals or their household contacts. (Dorland, 28th ed) Sabin Vaccine,Oral Poliovirus Vaccine,Vaccine, Oral Poliovirus,Vaccine, Sabin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000914 Antibodies, Viral Immunoglobulins produced in response to VIRAL ANTIGENS. Viral Antibodies
D014481 United States A country in NORTH AMERICA between CANADA and MEXICO.
D014613 Vaccines, Attenuated Live vaccines prepared from microorganisms which have undergone physical adaptation (e.g., by radiation or temperature conditioning) or serial passage in laboratory animal hosts or infected tissue/cell cultures, in order to produce avirulent mutant strains capable of inducing protective immunity. Attenuated Vaccine,Vaccines, Live, Attenuated,Attenuated Vaccines,Vaccine, Attenuated

Related Publications

Poliomyelitis prevention: enhanced-potency inactivated poliomyelitis vaccine--supplementary statement.
December 1987, MMWR. Morbidity and mortality weekly report,
Leads from the MMWR. Poliomyelitis prevention: enhanced-potency inactivated poliomyelitis vaccine--supplementary statement.
January 1988, JAMA,
Immunogenicity of enhanced potency inactivated polio vaccine.
November 1992, Indian pediatrics,
Clinical efficacy of a new, enhanced-potency, inactivated poliovirus vaccine.
April 1988, Lancet (London, England),
Measles prevention: supplementary statement.
January 1989, MMWR. Morbidity and mortality weekly report,
Mucosal immunity following oral poliovirus vaccine and enhanced potency inactivated poliovirus vaccine immunization.
December 1991, The Pediatric infectious disease journal,
The future roles of oral polio vaccine and enhanced potency inactivated polio vaccine.
December 1991, The Pediatric infectious disease journal,
[Effect of 2-phenoxyethanol on potency of Sabin inactivated poliomyelitis vaccine and its safety].
March 2007, Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology,
Serologic response to oral polio vaccine and enhanced-potency inactivated polio vaccines.
September 1988, American journal of epidemiology,
Fifteen years of experience with Vero-produced enhanced potency inactivated poliovirus vaccine.
March 1997, The Pediatric infectious disease journal,
Copied contents to your clipboard!